Mirvetuximab soravtansine approved in UK to treat adult patients who have ovarian, fallopian tube or primary peritoneal cancer

CAR-T Digest - August 2020

24 July 2025: Mirvetuximab soravtansine approved in UK to treat adult patients who have ovarian, fallopian tube or primary peritoneal cancer

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved Mirvetuximab soravtansine (Elahere) for adults with ovarian, fallopian tube, or primary peritoneal cancer that is FRα-positive and has become resistant to platinum-based chemotherapy, after one to three previous lines of treatment
The decision is backed by results from the Phase 3 MIRASOL trial, which involved 453 patients. The study showed that Elahere significantly extended progression-free survival to 5.6 months, compared to 4 months with standard chemotherapy, and overall survival to 16.5 months, versus 12.8 months with current treatments
The treatment specifically targets cancer cells with folate receptor-alpha (FRα), offering a more personalized therapy option for eligible patients
The approval was granted through the International Recognition Procedure, and the MHRA will continue to monitor its safety and effectiveness. Patients and healthcare professionals are encouraged to report any side effects via the yellow card scheme